Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

(MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expectations related to BioMarin's clinical trials of 6R-BH4 for proteinuria, pulmonary arterial hypertension and other indications, actions by regulatory authorities and the general development of BH4 for sickle cell. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 Minerva Neurosciences (NASDAQ: ... therapies to treat neuropsychiatric diseases and disorders, today announced ... vice president of finance and chief accounting officer, effective ... senior executive with more than 20 years of experience ... science companies. His background includes the management of compliance ...
(Date:7/14/2014)... July 14, 2014 PatientCrossroads, ... platform, announced that three PatientCrossroads-based patient registries—DuchenneConnect, ... Phelan-McDermid Syndrome International Registry; and the NephCure ... awarded contracts by the Patient-Centered Outcomes Research ... of a new health data network called ...
(Date:7/13/2014)... University) -- The discovery 30 years ago of soccer-ball-shaped ... of nanotechnology research. Now, there appears to be a ... University, Shanxi University and Tsinghua University in China have ... a hollow molecular cage similar to a carbon buckyball. ... structurepreviously only a matter of speculationdoes indeed exist. , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 2014 Deep ... is a professional and in-depth study on the current ... China. , The report provides a basic overview of ... Global market analysis and Chinese domestic market analysis are ... competitive landscape of the market. A comparison between the ...
Breaking Biology Technology:Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3
... but its repair could actually increase warming in the southern hemisphere, ... The Antarctic ozone ... but the discovery of a previously undiscovered feedback shows that it ... the past two decades. High-speed winds in the area ...
... , Jan. 25 Novavax, Inc. (Nasdaq: ... company will be presenting at the upcoming Phacilitate Vaccine Forum ... at the Grand Hyatt, Washington, D.C.  Mr. ... Alliances will be participating in a Focus Session: Fast ...
... AMSTERDAM, The Netherlands ... (Euronext: AMT), a leader in the field of,human ... the official,marketing authorisation process for its lead product ... The submission,of the Glybera(R) Marketing Authorisation Application (MAA), ...
Cached Biology Technology:Ozone hole healing could cause further climate warming 2NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010 2EMA Starts Formal Review of Glybera(R) Dossier 2EMA Starts Formal Review of Glybera(R) Dossier 3
(Date:7/11/2014)... German . ... the refraction of X-rays through a specimen instead of ... method are often of much higher quality than those ... Prof. Franz Pfeiffer are particularly interested in developing new ... X-ray phase-contrast imaging. One main goal is to make ...
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... IOF World Congress on Osteoporosis 2008 (IOF WCO), to ... registration to benefit from special early bird rates. The ... 3-7, 2008, is the worlds largest scientific congress devoted ... to IOF Members, Non-Members and Students or Fellows, with ...
... hereditary disorder that strongly predisposes carriers to develop cancer ... Asian female, report researchers today at the American Association ... Generally, a person should have two normal copies ... the disorder known as Li-Fraumeni syndrome (LFS), one defective ...
... announced the results of a systematic effort to map ... cause of cancer deaths. Appearing in the November 4 ... provides a comprehensive view of the abnormal genetic landscape ... regions that are frequently gained or lost in human ...
Cached Biology News:Rare cancer-causing syndrome found, for the first time, in Singapore 2Genome study charts genetic landscape of lung cancer 2Genome study charts genetic landscape of lung cancer 3
... Fujifilm Life Science LAS-3000mini is a ... to chemiluminescence applications, and the perfect ... Fuiji 's LAS-3000 provides significantly improved ... , Glowell calibration standards validate that ...
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... ScriptCap™ m7G Capping system ... and all of the components ... 0 on the end of ... These kits feature high efficiency ...
... Fujifilm Life Science FLA-5100 imaging system allows ... large as 40 x 46cm at a ... This system is especially suitable for protein ... array analysis for genomics., Fuji s FLA-5100 ...
Biology Products: